Doxorubicin liposomal companion diagnostic - Allarity Therapeutics
Alternative Names: Doxorubicin liposomal DRP™Latest Information Update: 28 Apr 2021
Price :
$50 *
At a glance
- Originator Oncology Venture
- Developer Allarity Therapeutics
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Breast-cancer in Denmark
- 07 Oct 2020 Oncology Venture A/S is now called Allarity Therapeutics
- 24 Aug 2018 Medical Prognosis Institute merged with Oncology Venture and the former changed its name to Oncology Venture A/S